We are live on ! Find out more
BIO icon

Bio-Rad Laboratories Class A

437 hedge funds and large institutions have $6.5B invested in Bio-Rad Laboratories Class A in 2024 Q3 according to their latest regulatory filings, with 68 funds opening new positions, 133 increasing their positions, 169 reducing their positions, and 68 closing their positions.

New
Increased
Maintained
Reduced
Closed

41% more call options, than puts

Call options by funds: $6.56M | Put options by funds: $4.64M

20% more capital invested

Capital invested by funds: $5.41B → $6.5B (+$1.09B)

0.72% more ownership

Funds ownership: 84.5%85.21% (+0.72%)

0% more funds holding in top 10

Funds holding in top 10: 66 (0)

0% more first-time investments, than exits

New positions opened: 68 | Existing positions closed: 68

0% less funds holding

Funds holding: 439437 (-2)

21% less repeat investments, than reductions

Existing positions increased: 133 | Existing positions reduced: 169

Holders
437
Holders Change
-2
Holders Change %
-0.46%
% of All Funds
6.28%
Holding in Top 10
6
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.09%
New
68
Increased
133
Reduced
169
Closed
68
Calls
$6.56M
Puts
$4.64M
Net Calls
+$1.91M
Net Calls Change
+$8.17M
Name Holding Trade Value Shares
Change
Change in
Stake
PI
201
PEAK6 Investments
Illinois
$956K +$907K +2,857 New
Pacer Advisors
202
Pacer Advisors
Pennsylvania
$941K +$74K +233 +9%
OAM
203
Oppenheimer Asset Management
New York
$893K -$15.9K -50 -2%
Corient Private Wealth
204
Corient Private Wealth
Florida
$891K +$28.9K +91 +4%
AI
205
Atria Investments
North Carolina
$885K +$70.8K +223 +9%
NICM
206
Neo Ivy Capital Management
New York
$878K +$834K +2,626 New
TRCT
207
Tower Research Capital (TRC)
New York
$864K +$575K +1,810 +234%
VOYA Investment Management
208
VOYA Investment Management
Georgia
$840K -$1.38M -4,336 -63%
NAM
209
Nissay Asset Management
Japan
$830K +$20K +63 +3%
OTL
210
Oak Thistle LLC
New York
$821K +$415K +1,306 +114%
Jane Street
211
Jane Street
New York
$817K -$3.62M -11,407 -82%
MWM
212
Moran Wealth Management
Florida
$786K -$15.9K -50 -2%
Brown Advisory
213
Brown Advisory
Maryland
$769K -$388K -1,222 -35%
FAF
214
Fjarde Ap-fonden
Sweden
$763K +$724K +2,280 New
ETC
215
Exchange Traded Concepts
Oklahoma
$760K -$281K -884 -28%
BCM
216
Bayesian Capital Management
New York
$757K -$318K -1,000 -31%
Pathstone Holdings
217
Pathstone Holdings
New Jersey
$753K -$37.8K -119 -5%
SOADOR
218
State of Alaska Department of Revenue
Alaska
$744K -$12.7K -40 -2%
Prudential Financial
219
Prudential Financial
New Jersey
$731K -$4.17M -13,144 -86%
BC
220
Brio Consultants
California
$727K -$138K -433 -17%
Public Employees Retirement Association of Colorado
221
Public Employees Retirement Association of Colorado
Colorado
$698K
Nordea Investment Management
222
Nordea Investment Management
Sweden
$684K -$1.26M -3,958 -66%
PAM
223
Panagora Asset Management
Massachusetts
$670K -$318 -1 -0%
RC
224
Rovin Capital
Arizona
$669K +$635K +1,999 New
M&T Bank
225
M&T Bank
New York
$662K -$65.4K -206 -9%

BIO Hedge Fund Activity: Q3 2024 in Review

437 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q3 2024, worth a combined $6.5B — up 20% from $5.41B a quarter earlier.

Fund positioning in BIO was balanced in Q3 2024: 68 funds opened new positions, 68 closed out, 133 added to existing stakes and 169 trimmed.

The largest buyer was VanEck Associates, adding an estimated $205M. The largest seller was Invesco, cutting an estimated $161M.

  • 437 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q3 2024, down from 439 in Q2 2024.
  • Funds reported $6.5B of Bio-Rad Laboratories Class A stock for Q3 2024, up 20% quarter-over-quarter.
  • 68 funds opened new Bio-Rad Laboratories Class A positions in Q3 2024 and 68 closed out, a net change of 0 holders.
  • The largest Bio-Rad Laboratories Class A buyer in Q3 2024 was VanEck Associates, an estimated $205M added.
  • The largest Bio-Rad Laboratories Class A seller in Q3 2024 was Invesco, an estimated $161M sold.

Based on aggregated 13F filings for Q3 2024.